Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 01期
关键词：
D O I：
10.1016/j.juro.2016.10.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [1] Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer
    Veccia, Antonello
    Caffo, Orazio
    De Giorgi, Ugo
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Aieta, Michele
    Facchini, Gaetano
    Mansueto, Giovanni
    Mattioli, Rodolfo
    Procopio, Giuseppe
    Zagonel, Vittorina
    D'Angelo, Alessandro
    Spizzo, Gilbert
    Bortolus, Roberto
    Donini, Maddalena
    Lo Re, Giovanni
    Massari, Francesco
    Vicario, Giovanni
    Zucali, Paolo A.
    Alesini, Daniele
    Bonetti, Andrea
    Mucciarini, Claudia
    Nicodemo, Maurizio
    Berruti, Alfredo
    Fratino, Lucia
    Lodde, Michele
    Messina, Caterina
    Perin, Alessandra
    Santini, Daniele
    Sava, Teodoro
    Tucci, Marcello
    Basso, Umberto
    Maines, Francesca
    Burgio, Luca S.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2016, 12 (04) : 493 - 502
  • [2] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
  • [3] Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel
    Buttigliero, Consuelo
    Tucci, Marcello
    Vignani, Francesca
    Di Stefano, Rosario F.
    Leone, Gianmarco
    Zichi, Clizia
    Pignataro, Daniele
    Lacidogna, Gaetano
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio, V
    Di Maio, Massimo
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : 318 - 324
  • [4] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [5] Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following first-line docetaxel
    Heidenreich, A.
    Pfister, D. J.
    Thueer, D.
    Brehmer, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors
    Caffo, Orazio
    Pappagallo, Giovanni
    Brugnara, Sonia
    Caldara, Alessia
    di Pasquale, Maria Chiara
    Ferro, Antonella
    Frisinghelli, Michela
    Murgia, Viviana
    Russo, Lucianna Maria
    Soini, Barbara
    Valduga, Francesco
    Veccia, Antonello
    Galligioni, Enzo
    UROLOGY, 2012, 79 (03) : 644 - 649
  • [7] Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Beuzeboc, Philippe
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Greilsamer, Charlotte
    Hon, Thierry Nguyen Tan
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Ratta, Raffaele
    Flechon, Aude
    Cheneau, Caroline
    Maillard, Aline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    EUROPEAN UROLOGY, 2022, 81 (03) : 234 - 240
  • [8] Docetaxel A Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer
    McKeage, Kate
    DRUGS, 2012, 72 (11) : 1559 - 1577
  • [9] The Oncological Outcomes and Risk Stratification in Docetaxel Chemotherapy for Castration-resistant Prostate Cancer
    Shiota, Masaki
    Yokomizo, Akira
    Adachi, Takumi
    Koga, Hirofumi
    Yamaguchi, Akito
    Imada, Kenjiro
    Takeuchi, Ario
    Kiyoshima, Keijiro
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Naito, Seiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (09) : 860 - 867
  • [10] Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?
    Kongsted, Per
    Svane, Inge Marie
    Lindberg, Henriette
    Daugaard, Gedske
    Sengelov, Lisa
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (11) : 494.e15 - 494.e20
12345